Product Code: GDHC4318CTIDB
GlobalData's clinical trial report, "Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2017" provides an overview of Cognitive Impairment Associated With Schizophrenia (CIAS) clinical trials scenario. This report provides top line data relating to the clinical trials on Cognitive Impairment Associated With Schizophrenia (CIAS). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents
Table of Contents 2
- List of Tables 3
- List of Figures 4
- Report Guidance 5
- GlobalData Clinical Trials Report Coverage 6
- Clinical Trials by Region 7
- Clinical Trials and Average Enrollment by Country 8
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
- Top Five Countries Contributing to Clinical Trials in Europe 12
- Top Countries Contributing to Clinical Trials in North America 13
- Top Countries Contributing to Clinical Trials in Middle East and Africa 14
- Top Countries Contributing to Clinical Trials in Central and South America 15
- Clinical Trials by G7 Countries: Proportion of Cognitive Impairment Associated With Schizophrenia (CIAS) to Central Nervous System Clinical Trials 16
- Clinical Trials by Phase in G7 Countries 18
- Clinical Trials in G7 Countries by Trial Status 19
- Clinical Trials by E7 Countries: Proportion of Cognitive Impairment Associated With Schizophrenia (CIAS) to Central Nervous System Clinical Trials 21
- Clinical Trials by Phase in E7 Countries 23
- Clinical Trials in E7 Countries by Trial Status 24
- Clinical Trials by Phase 25
- In Progress Trials by Phase 26
- Clinical Trials by Trial Status 27
- Clinical Trials by End Point Status 29
- Subjects Recruited Over a Period of Time 30
- Clinical Trials by Sponsor Type 31
- Prominent Sponsors 32
- Top Companies Participating in Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials 34
- Prominent Drugs 36
- Clinical Trial Profile Snapshots 38
Appendix 80
- Abbreviations 80
- Definitions 80
- Research Methodology 81
- Secondary Research 81
- About GlobalData 82
- Contact Us 82
- Source 82
List of Tables
List of Tables
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials by Region, 2017* 7
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 14
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 15
- Proportion of Cognitive Impairment Associated With Schizophrenia (CIAS) to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 17
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
- Proportion of Cognitive Impairment Associated With Schizophrenia (CIAS) to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 22
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials by Phase, 2017* 25
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 26
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 28
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 29
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 30
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 31
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 33
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 35
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37
List of Figures
List of Figures
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 14
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 15
- Proportion of Cognitive Impairment Associated With Schizophrenia (CIAS) to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 16
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
- Proportion of Cognitive Impairment Associated With Schizophrenia (CIAS) to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 21
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 25
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 26
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 27
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 29
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 30
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 31
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 32
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 34
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 36
- GlobalData Methodology 81
